Dabigatran

Summary

Dabigatran (CHEMBL48361) is an approved small-molecule anticoagulant targeting F2; indicated across 11 conditions including venous thromboembolism and atrial fibrillation.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (F2)
• Indications: 11 conditions
• Clinical trials: 95
• Chemistry: 471.5 Da · C25H25N7O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL48361
Name	Dabigatran
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	216210
ChEBI	CHEBI:70752
Molecular formula	C25H25N7O3
Molecular weight	471.5
InChIKey	YBSJFWOBGCMAKL-UHFFFAOYSA-N

SMILES: CN1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N

IUPAC name: 3-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid

ChEBI definition: An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-β-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism.

Pharmacological roles (ChEBI): anticoagulant, EC 3.4.21.5 (thrombin) inhibitor, EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor.

Also known as: BIBR 953 ZW, BIBR-953, Dabigatran, Pradaxa (dabigatran), DABIGATRAN, dabigatran, SID174006835, BIBR 953 (DABIGATRAN ETEXILATE, PRADAXA), BIBR 953 (Dabigatran etexilate; Pradaxa)

Patent coverage: 3,783 distinct patent families (13,443 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 13,433 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
F2	coagulation factor II, thrombin	Inhibition	8.3	1.4%	P00734

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Solute carrier family 22 member 2, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Plasminogen, Tissue-type plasminogen activator, Prothrombin, Serine protease hepsin, Trypsin, Coagulation factor X, Ribosyldihydronicotinamide dehydrogenase [quinone], Vitamin K-dependent protein C.

Bioactivity

ChEMBL activities: 31 potent at pChembl ≥ 5 of 36 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
F2	8.92	IC50	1.2	nM	CHEMBL_ACT_16666543
F2	8.92	IC50	1.2	nM	CHEMBL_ACT_18006930
F2	8.91	IC50	1.23	nM	CHEMBL_ACT_16580449
F2	8.91	IC50	1.23	nM	CHEMBL_ACT_16580461
F2	8.66	IC50	2.2	nM	CHEMBL_ACT_15760230
F2	8.58	IC50	2.61	nM	CHEMBL_ACT_15213382
F2	8.58	IC50	2.63	nM	CHEMBL_ACT_16414136
F2	8.58	IC50	2.61	nM	CHEMBL_ACT_24773419
F2	8.35	Ki	4.5	nM	CHEMBL_ACT_1096883
F2	8.35	Ki	4.5	nM	CHEMBL_ACT_11022296
F2	8.35	Ki	4.5	nM	CHEMBL_ACT_13843685
F2	8.35	Ki	4.5	nM	CHEMBL_ACT_18652546
F2	8.35	Ki	4.5	nM	CHEMBL_ACT_22431958
F2	8.22	IC50	6	nM	CHEMBL_ACT_16817213
F2	8.2	Ki	6.3	nM	CHEMBL_ACT_13338495
F2	8.2	Ki	6.3	nM	CHEMBL_ACT_8040628
F2	8.19	IC50	6.4	nM	CHEMBL_ACT_22431959
F2	8.15	IC50	7	nM	CHEMBL_ACT_29112145
F2	8.03	IC50	9.3	nM	CHEMBL_ACT_1096882
F2	8.03	IC50	9.3	nM	CHEMBL_ACT_18535343
F2	8	IC50	10	nM	CHEMBL_ACT_12205113
F2	7.4	IC50	40	nM	CHEMBL_ACT_25587780
PRSS1	7.3	Ki	50.3	nM	CHEMBL_ACT_1096885
PRSS1	7.3	Ki	50	nM	CHEMBL_ACT_18652547
HPN	6.08	Ki	835	nM	CHEMBL_ACT_15176560
PLG	5.77	Ki	1695	nM	CHEMBL_ACT_1096886
F10	5.42	Ki	3760	nM	CHEMBL_ACT_1096884
F10	5.42	Ki	3800	nM	CHEMBL_ACT_22431923
SLC22A2	5.33	IC50	4700	nM	CHEMBL_ACT_12636173
F10	5.24	IC50	5800	nM	CHEMBL_ACT_25587872
SLC47A1	5.09	IC50	8100	nM	CHEMBL_ACT_12637805

Target pathways

Aggregated over 1 target gene(s): F2.

Top Reactome pathways

38 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	F2
R-HSA-140837	1	F2
R-HSA-140875	1	F2
R-HSA-140877	1	F2
Gamma-carboxylation of protein precursors	1	F2
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus	1	F2
Removal of aminoterminal propeptides from gamma-carboxylated proteins	1	F2
Gamma-carboxylation, transport, and amino-terminal cleavage of proteins	1	F2
Signal Transduction	1	F2
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1	F2
Disease	1	F2
Complement cascade	1	F2
Innate Immune System	1	F2
Immune System	1	F2
Cell surface interactions at the vascular wall	1	F2
Signaling by GPCR	1	F2
Class A/1 (Rhodopsin-like receptors)	1	F2
Peptide ligand-binding receptors	1	F2
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	1	F2
GPCR downstream signalling	1	F2
Metabolism of proteins	1	F2
G alpha (q) signalling events	1	F2
Thrombin signalling through proteinase activated receptors (PARs)	1	F2
GPCR ligand binding	1	F2
Post-translational protein modification	1	F2
Platelet activation, signaling and aggregation	1	F2
Platelet Aggregation (Plug Formation)	1	F2
R-HSA-9651496	1	F2
Defective factor XII causes hereditary angioedema	1	F2
Defective factor VIII causes hemophilia A	1	F2
Diseases of hemostasis	1	F2
Defective F8 cleavage by thrombin	1	F2
Fibrin formation	1	F2
Initiation of coagulation cascade	1	F2
Regulation of clotting cascade	1	F2
Amplification and propagation of coagulation cascade	1	F2
Regulation of Complement cascade	1	F2
Dengue Virus-Host Interactions	1	F2

Dominant GO biological processes

GO term	Targets
proteolysis	1
acute-phase response	1
cell surface receptor signaling pathway	1
blood coagulation	1
positive regulation of cell population proliferation	1
regulation of cell shape	1
response to wounding	1
negative regulation of platelet activation	1
platelet activation	1
regulation of blood coagulation	1
positive regulation of blood coagulation	1
negative regulation of blood coagulation	1
positive regulation of cell growth	1
positive regulation of insulin secretion	1
positive regulation of collagen biosynthetic process	1

Indications & clinical

Indications

7 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
venous thromboembolism	3	MONDO:0005399	EFO:0004286
atrial fibrillation	3	MONDO:0004981	EFO:0000275
injury	3	MONDO:0021178	EFO:0000546
stroke disorder	3	MONDO:0005098	EFO:0000712
cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1	2	MONDO:0000914	MONDO:0000914
kidney failure	1	MONDO:0001106	HP:0000083
respiratory syncytial virus infectious disease	1	MONDO:0001577	EFO:1001413

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 95.

Phase distribution

Phase	Trials
Not specified	43
PHASE4	19
PHASE1	15
PHASE3	10
PHASE2	6
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03568890	PHASE4	ACTIVE_NOT_RECRUITING	Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
NCT06650501	PHASE4	RECRUITING	Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
NCT01210755	PHASE4	COMPLETED	Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
NCT01339819	PHASE4	COMPLETED	Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
NCT01352702	PHASE4	TERMINATED	Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
NCT01468155	PHASE4	COMPLETED	DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation
NCT01478282	PHASE4	UNKNOWN	Reversal of the Antithrombotic Action of New Oral Anticoagulants
NCT01812200	PHASE4	COMPLETED	Antithrombotic Triple Therapy in Humans
NCT01994265	PHASE4	COMPLETED	Cognitive Impairment Related to Atrial Fibrillation Prevention Trial
NCT02067182	PHASE4	COMPLETED	Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation
NCT02331602	PHASE4	UNKNOWN	Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
NCT02389582	PHASE4	COMPLETED	Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease
NCT02596555	PHASE4	TERMINATED	Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
NCT02723981	PHASE4	WITHDRAWN	COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
NCT02935855	PHASE4	COMPLETED	ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
NCT02982850	PHASE4	COMPLETED	Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease
NCT03463317	PHASE4	COMPLETED	Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
NCT03536611	PHASE4	UNKNOWN	Dabigatran Versus Warfarin With NVAF Who Undergo PCI
NCT04688723	PHASE4	UNKNOWN	Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
NCT06818279	PHASE2/PHASE3	NOT_YET_RECRUITING	Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis
NCT00329238	PHASE3	COMPLETED	Secondary Prevention of Venous Thrombo Embolism (VTE).
NCT01431456	PHASE3	COMPLETED	Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
NCT01661101	PHASE3	COMPLETED	Management of Myocardial Injury After Noncardiac Surgery Trial
NCT01675076	PHASE3	COMPLETED	Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
NCT01868243	PHASE2/PHASE3	TERMINATED	Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively
NCT02313584	PHASE3	UNKNOWN	Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk
NCT02544932	PHASE3	UNKNOWN	Pleotropic Effect of New Oral Anticoagulants
NCT03153150	PHASE3	COMPLETED	Start or STop Anticoagulants Randomised Trial (SoSTART)
NCT03181386	PHASE3	COMPLETED	Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants
NCT03961334	PHASE3	UNKNOWN	MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
NCT03996772	PHASE3	COMPLETED	PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
NCT00818753	PHASE2	COMPLETED	Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention
NCT01361763	PHASE2	UNKNOWN	Safety Study of Dabigatran in CADASIL
NCT02223260	PHASE2	COMPLETED	Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
NCT02295826	PHASE2	COMPLETED	Dabigatran Following Transient Ischemic Attack and Minor Stroke
NCT02872649	PHASE2	TERMINATED	Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)
NCT04002011	PHASE2	WITHDRAWN	DOAC Versus VKA After Cardiac Surgery
NCT01688830	PHASE1	COMPLETED	Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate
NCT02028780	PHASE1	COMPLETED	Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects
NCT02102633	PHASE1	COMPLETED	Drug Interaction Study Between Bosutinib And Dabigatran
NCT02171039	PHASE1	COMPLETED	Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers
NCT02171533	PHASE1	COMPLETED	Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers
NCT02361619	PHASE1	COMPLETED	Dabigatran in an Interaction Probe Drug Cocktail
NCT02524210	PHASE1	COMPLETED	Effect of Inhibitors of the Proton Pump on Intestinal Transporters
NCT03311841	PHASE1	COMPLETED	Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
NCT03742336	PHASE1	COMPLETED	Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants
NCT03752294	PHASE1	WITHDRAWN	A Novel Therapeutic Target for Alzheimer’s Disease in Men and Women 50-85 Years of Age.
NCT04498741	PHASE1	COMPLETED	Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
NCT04782076	PHASE1	COMPLETED	A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
NCT04809818	PHASE1	COMPLETED	A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
NCT05064800	PHASE1	COMPLETED	PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
NCT06945276	PHASE1	COMPLETED	Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers
NCT04618913	Not specified	ACTIVE_NOT_RECRUITING	Anticoagulation in Patients With Venous Thromboembolism and Cancer
NCT05038228	Not specified	ACTIVE_NOT_RECRUITING	High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
NCT06449469	Not specified	ACTIVE_NOT_RECRUITING	The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)
NCT07083609	Not specified	RECRUITING	Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam
NCT07358416	Not specified	ACTIVE_NOT_RECRUITING	Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
NCT01153698	Not specified	TERMINATED	Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
NCT01852162	Not specified	COMPLETED	Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
NCT02085824	Not specified	UNKNOWN	Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
NCT02149303	Not specified	COMPLETED	Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
NCT02415855	Not specified	COMPLETED	Canadian Pradaxa Acute Stroke Safety Study
NCT02631057	Not specified	COMPLETED	Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan
NCT02640222	Not specified	COMPLETED	APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
NCT02687867	Not specified	COMPLETED	Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist
NCT02742480	Not specified	UNKNOWN	Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)
NCT02744092	Not specified	COMPLETED	Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
NCT02754154	Not specified	COMPLETED	Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
NCT02769078	Not specified	COMPLETED	Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
NCT02792335	Not specified	COMPLETED	Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
NCT02849509	Not specified	COMPLETED	Patient Convenience Study- NIS RELATE
NCT02864758	Not specified	COMPLETED	Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
NCT02885961	Not specified	UNKNOWN	The Coagulation Cascade in Idiopathic Pulmonary Fibrosis
NCT02904499	Not specified	COMPLETED	Use of Public Health Surveillance Models in the French National Health System Database
NCT03119116	Not specified	COMPLETED	Use of Direct Oral Anticoagulants in UK
NCT03189069	Not specified	COMPLETED	A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage
NCT03254134	Not specified	COMPLETED	Comparative Effectiveness and Safety Between Warfarin and Dabigatran
NCT03254147	Not specified	COMPLETED	Medical Need of OAC Reversal
NCT03258645	Not specified	COMPLETED	This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke
NCT03441633	Not specified	COMPLETED	Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
NCT03572972	Not specified	COMPLETED	Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
NCT03684395	Not specified	COMPLETED	Accessibility to New Drugs Versus SOC in Sweden
NCT04042155	Not specified	UNKNOWN	Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)
NCT04249401	Not specified	COMPLETED	Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)
NCT04297150	Not specified	UNKNOWN	Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..
NCT04433481	Not specified	UNKNOWN	Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis
NCT04532528	Not specified	COMPLETED	ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years
NCT04593043	Not specified	COMPLETED	Replication of the RELY Anticoagulant Trial in Healthcare Claims Data
NCT04662515	Not specified	COMPLETED	NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
NCT04735523	Not specified	COMPLETED	Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
NCT04808934	Not specified	WITHDRAWN	NOAC Portuguese Real World Study
NCT04878497	Not specified	UNKNOWN	Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
NCT05022563	Not specified	COMPLETED	Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
NCT05838664	Not specified	COMPLETED	A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
NCT06144866	Not specified	UNKNOWN	Evaluataion of NOAC Levels in Acute Stroke

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

50 molecules share ≥1 primary target. Top 50 by shared-target count:

Molecule	Source	Status	Shared targets
APIXABAN	ChEMBL + PubChem	Phase 4 (approved)	F2
EDOXABAN	ChEMBL + PubChem	Phase 4 (approved)	F2
ARGATROBAN	ChEMBL	Phase 4 (approved)	F2
BENZOYL PEROXIDE	ChEMBL	Phase 4 (approved)	F2
BETRIXABAN	ChEMBL	Phase 4 (approved)	F2
BIVALIRUDIN	ChEMBL	Phase 4 (approved)	F2
BORTEZOMIB	ChEMBL	Phase 4 (approved)	F2
CAPTOPRIL	ChEMBL	Phase 4 (approved)	F2
CIANIDANOL	ChEMBL	Phase 4 (approved)	F2
DABIGATRAN ETEXILATE	ChEMBL	Phase 4 (approved)	F2
DEQUALINIUM	ChEMBL	Phase 4 (approved)	F2
GENTIAN VIOLET	ChEMBL	Phase 4 (approved)	F2
HEXAMIDINE	ChEMBL	Phase 4 (approved)	F2
INDIGOTINDISULFONATE	ChEMBL	Phase 4 (approved)	F2
LIOTHYRONINE	ChEMBL	Phase 4 (approved)	F2
LUSUTROMBOPAG	ChEMBL	Phase 4 (approved)	F2
MELAGATRAN	ChEMBL	Phase 4 (approved)	F2
METHYLPREDNISOLONE	ChEMBL	Phase 4 (approved)	F2
PENTAMIDINE	ChEMBL	Phase 4 (approved)	F2
RIVAROXABAN	ChEMBL	Phase 4 (approved)	F2
SUCCIMER	ChEMBL	Phase 4 (approved)	F2
SULFAGUANIDINE	ChEMBL	Phase 4 (approved)	F2
TELOTRISTAT	ChEMBL	Phase 4 (approved)	F2
XIMELAGATRAN	ChEMBL	Phase 4 (approved)	F2
CAMOSTAT	ChEMBL	Phase 3	F2
CAMOSTAT MESILATE	ChEMBL	Phase 3	F2
GABEXATE	ChEMBL	Phase 3	F2
MILVEXIAN	ChEMBL	Phase 3	F2
NAFAMOSTAT	ChEMBL	Phase 3	F2
QUERCETIN	ChEMBL	Phase 3	F2
SILIBININ	ChEMBL	Phase 3	F2
BMS-986141	ChEMBL	Phase 2	F2
CETRAXATE	ChEMBL	Phase 2	F2
DIBROMPROPAMIDINE	ChEMBL	Phase 2	F2
EFEGATRAN	ChEMBL	Phase 2	F2
FIDEXABAN	ChEMBL	Phase 2	F2
GW813893	ChEMBL	Phase 2	F2
INOGATRAN	ChEMBL	Phase 2	F2
LETAXABAN	ChEMBL	Phase 2	F2
NAPSAGATRAN	ChEMBL	Phase 2	F2
PROFLAVINE	ChEMBL	Phase 2	F2
RAZAXABAN	ChEMBL	Phase 2	F2
SEGATROXABAN	ChEMBL	Phase 2	F2
TANOGITRAN	ChEMBL	Phase 2	F2
Echothiophate	PubChem	Approved	F2
Pimavanserin	PubChem	Approved	F2
Propylene Glycol	PubChem	Approved	F2
Pyrazinamide	PubChem	Approved	F2
Pyridoxine	PubChem	Approved	F2
Vorapaxar	PubChem	Approved	F2